Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)Ramón García‐Sánz, Carmen Martı́nez, Anna Sureda et al.|Annals of Oncology|2019Cited by 129
FNDC4 and FNDC5 Attenuate SARS‐CoV‐2 S1‐Induced Inflammatory Responses in Human Adipose TissueGabriela Neira, Á. Rodríguez, Marina Martín et al.|European Journal of Clinical Investigation|2026Cited by 0